Seven decades of clinical experience with Wilson's disease: Report from the national reference centre in Poland
European Journal of Neurology · 2024-11 · 31 (11)
DOI: 10.1111/ene.15646 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 11.12.2022. Verfasst von Anna Członkowska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland. Hauptthemen laut MEDLINE: Hepatolenticular Degeneration. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and purpose Wilson's disease (WD) is a rare autosomal recessive disorder causing excessive copper deposition and a spectrum of manifestations, particularly neurological and hepatic symptoms. We analysed the clinical characteristics of patients with WD admitted to the country's only reference centre, which provided long‐term care to most adult patients in Poland over seven decades (pre‐1959 to 2019).
Methods
Electronic prospective data collection began in the 2000s and, for prior years, medical records were analysed retrospectively. Demographic and clinical characteristics, treatment and outcomes were analysed by decade of diagnosis. Life‐years lost were estimated in patients with WD compared with the general population. Kaplan–Meier curves were used for a time‐to‐death analysis using 2000–2009 as a reference.
Results
In total, 929 patients were analysed. The number of patients increased from 21 before 1959 to 315 for 2000 to 2009 period. Mostly males were diagnosed before the 1990s, but the numbers of female patients diagnosed increased thereafter. Initially, most patients presented with neurological manifestations; however, the incidence of hepatic manifestations and asymptomatic presentations increased over time as patients were diagnosed early and consequently were more independent at diagnosis. Fewer Kayser‐Fleischer rings were detected recently. Prior to 1970, patients were treated with D‐penicillamine (DP); however, since the introduction of zinc, both therapies have been used as often. Since the 1990s, switches between DP and zinc were recorded in 6%–7% of patients. Consistent improvement in survival has been observed over the years.
Conclusions
This is the largest cohort of patients with WD reported in Poland, with the longest follow‐up. Earlier diagnosis and prognosis have improved over seven decades.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
- Decision Analysis and Support Unit, Warsaw School of Economics, Warsaw, Poland.
ORCID-Profile: Anna Członkowska, Maciej Niewada
Zitieren
APA
Członkowska, A., Niewada, M., Litwin, T., Kraiński, Ł., Skowrońska, M., Piechal, A., Antos, A., Misztal, M., Khanna, I., & Kurkowska-Jastrzębska, I. (2024). Seven decades of clinical experience with Wilson's disease: Report from the national reference centre in Poland. European Journal of Neurology, 31(11). https://doi.org/10.1111/ene.15646
Vancouver
Członkowska A, Niewada M, Litwin T, Kraiński Ł, Skowrońska M, Piechal A, et al. Seven decades of clinical experience with Wilson's disease: Report from the national reference centre in Poland. European Journal of Neurology. 2024;31(11). doi:10.1111/ene.15646
BibTeX
@article{Czonkowska2024,
author = {Członkowska, Anna and Niewada, Maciej and Litwin, Tomasz and Kraiński, Łukasz and Skowrońska, Marta and Piechal, Agnieszka and Antos, Agnieszka and Misztal, Monika and Khanna, Ishani and Kurkowska-Jastrzębska, Iwona},
title = {Seven decades of clinical experience with Wilson's disease: Report from the national reference centre in Poland},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {11},
doi = {10.1111/ene.15646}
}
EUVIMED